AstraZeneca PLC on Tuesday said the U.S. Food and Drug Administration has accepted a supplemental biologics license application for Imfinzi, granting the drug Priority Review status.
Imfinzi is being developed to treat patients with stage 3 unresectable non-small cell lung cancer whose disease hasn’t progressed after some chemoradiation therapy.
Imfinzi has had positive data from a phase 3 trial, which continues to evaluate overall survival, one of its primary endpoints.
Source: Marketwatch
